Revised SPC: Taltz (ixekizumab) 80 mg solution for injection in pre-filled syringe

The SPC has been updated to include long-term safety and efficacy data from studies in plaque psoriasis (UNCOVER studies; through 5 years) and psoriatic arthritis (SPIRIT-P1 and -P2; 3 years), and results of the IXORA-R study, which compared ixekizumab to guselkumab in psoriasis

Source:

electronic Medicines compendium